James Burrows

James Burrows is a Senior Lecturer in the School of Pharmacy Material and Advanced Technologies for Healthcare at Queen's University Belfast. His research focuses on proteases, particularly their role in immune signaling and disease, including the DUB/USP17 family of deubiquitinating enzymes and bacterial proteases as antimicrobial targets. He is part of the Future Medicines Institute and has led projects like the KTP/Causeway Sensors Ltd collaboration. He actively supervises PhD students and contributes to drug delivery and enzyme inhibition research.

Research interests include USP17's role in cancer therapy, bacterial protease immune evasion, and nanoparticle-based drug delivery. His work integrates molecular biology, pharmacology, and biomedical engineering to advance therapeutic strategies.

Notable projects include the Future Medicines Institute (2024–present) and the study of bacterial proteases' immune subversion (2012–ongoing). He collaborates internationally, with publications in journals like International Journal of Pharmaceutics and Frontiers in Pharmacology.

He advises on PhD projects targeting proteases in cancer and antimicrobial strategies and has contributed to grants totaling over £3.5M. His lab focuses on enzyme regulation and drug delivery systems for biomedical applications.